Brief: PhaseBio Reports VANGARD trial discontinued due to COVID-19 treatment landscape

PhaseBio Pharmaceuticals

23/10/2020 13:15

Oct 23 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO PROVIDES PEMZIVIPTADIL (PB1046) PROGRAM UPDATE
    * PHASEBIO PHARMACEUTICALS - VANGARD TRIAL DISCONTINUED DUE
TO
EVOLVING COVID-19 TREATMENT LANDSCAPE
    * PHASEBIO PHARMACEUTICALS - VANGARD TRIAL DISCONTINUED DUE
TO
RECENT FEEDBACK FROM FDA REGARDING REGULATORY AND DEVELOPMENT
PATH
    * PHASEBIO PHARMACEUTICALS - VANGARD TRIAL DISCONTINUED DUE
TO
INTERIM ANALYSIS OF TRIAL DATA
    * PHASEBIO PHARMACEUTICALS - ENROLLMENT EXPECTED TO RESUME
FOR
ONGOING PHASE 2B TRIAL OF PEMZIVIPTADIL IN PULMONARY ARTERIAL
HYPERTENSION (PAH)
    * PHASEBIO PHARMACEUTICALS - PEMZIVIPTADIL WAS GENERALLY
WELL
TOLERATED, THERE WAS NO ADVERSE SAFETY SIGNAL REPORTED IN
VANGARD TRIAL
    * PHASEBIO PHARMACEUTICALS - FDA HIGHLIGHTED NEED FOR
ADDITIONAL
CLINICAL TRIALS WITH SUFFICIENT SAMPLE SIZE TO ADEQUATELY ASSESS
MORTALITY RISK
    * PHASEBIO PHARMACEUTICALS - RESULTS FROM VIP TRIAL ARE
EXPECTED
TO BE REPORTED IN H2 2021
    * PHASEBIO PHARMACEUTICALS - BASED ON VANGARD TRIAL INTERIM
ANALYSIS, DID NOT OBSERVE ANY DATA TRENDS IN 40 MG OR 100 MG
PEMZIVIPTADIL-TREATED ARMS

Source text for Eikon:  ID:nBw1wlw51a 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))